HomeCompareAHKSY vs PFE

AHKSY vs PFE: Dividend Comparison 2026

AHKSY yields 2.70% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $25.0K in total portfolio value· pulled ahead in Year 9
10 years
AHKSY
AHKSY
● Live price
2.70%
Share price
$20.04
Annual div
$0.54
5Y div CAGR
3.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$456.32
Full AHKSY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — AHKSY vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAHKSYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AHKSY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AHKSY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AHKSY
Annual income on $10K today (after 15% tax)
$229.08/yr
After 10yr DRIP, annual income (after tax)
$387.87/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $21,932.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AHKSY + PFE for your $10,000?

AHKSY: 50%PFE: 50%
100% PFE50/50100% AHKSY
Portfolio after 10yr
$37.0K
Annual income
$13,357.52/yr
Blended yield
36.06%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

AHKSY
No analyst data
Altman Z
2.2
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AHKSY buys
0
PFE buys
0
No recent congressional trades found for AHKSY or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAHKSYPFE
Forward yield2.70%6.13%
Annual dividend / share$0.54$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR3.3%13.2%
Portfolio after 10y$24.5K$49.6K
Annual income after 10y$456.32$26,258.71
Total dividends collected$3.6K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AHKSY vs PFE ($10,000, DRIP)

YearAHKSY PortfolioAHKSY Income/yrPFE PortfolioPFE Income/yrGap
1$10,978$278.39$9,153$693.39+$1.8KAHKSY
2$12,042$295.06$8,593$849.25+$3.4KAHKSY
3$13,197$312.46$8,336$1,066.78+$4.9KAHKSY
4$14,452$330.60$8,437$1,384.80+$6.0KAHKSY
5$15,813$349.50$9,013$1,875.40+$6.8KAHKSY
6$17,289$369.19$10,306$2,680.72+$7.0KAHKSY
7$18,889$389.70$12,820$4,101.38+$6.1KAHKSY
8$20,622$411.04$17,673$6,826.70+$2.9KAHKSY
9← crossover$22,499$433.24$27,543$12,591.86$5.0KPFE
10$24,530$456.32$49,560$26,258.71$25.0KPFE

AHKSY vs PFE: Complete Analysis 2026

AHKSYStock

Asahi Kasei Corporation manufactures, processes, and sells chemical products in Japan and internationally. The company operates through three segments: Material, Homes, and Health Care. It provides caustic soda, chemical fertilizers, nitric acid, ammonia, acrylonitrile, methyl methacrylate, styrene, adipic acid, hexamethylene diamine, AH salt, propionitrile, sodium cyanide, acetonitrile, methacrylonitrile, cyclohexyl methacrylate, cyclohexanol, cyclohexane, and cyclohexene; polymers; chemical intermediates; additives; membranes and systems; clads and anchors; optical and printing materials; electronic materials; and lithium-ion battery and lead-acid battery separators. The company offers cupro fiber, lining fabric, stretch fiber, spunbond nonwovens, cupro nonwoven fabric, microfiber suede, oil-water separator, multifunctional nonwoven, deodorizing nonwoven, heat-press formable thermoplastic nonwoven, noise suppression sheet, nylon filaments, flame-resistant fiber, honeycomb fabric, cellulose nanobead, ecorise, biocradle, and bemliese products, as well as polymers; synthetic rubber; elastomers; kitchen and household products; cleaners; and packaging products. In addition, the company provides electronic devices; and autoclaved aerated concrete, foundation systems, insulation materials, and structural systems and components. Further, it involved in the construction of homes and apartments; management of rental units and condominiums; brokerage of used homes; remodeling; and mortgage financing, asset management services, and insurance products. Additionally, the company provides pharmaceuticals and diagnostic reagents; dialyzers; therapeutic apheresis; biotherapeutics and plasma derivative filters and equipment, and virus removal filters; leukocyte reduction filters; defibrillators, temperature management systems, and data solutions; and UVC LED products. Asahi Kasei Corporation was founded in 1922 and is headquartered in Tokyo, Japan.

Full AHKSY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this AHKSY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AHKSY vs SCHDAHKSY vs JEPIAHKSY vs OAHKSY vs KOAHKSY vs MAINAHKSY vs JNJAHKSY vs MRKAHKSY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.